Advancing Opioid Use Disorder Treatment: A Narrative Review of Evidence-Based Solutions to Systems-Level Barriers in the US.

IF 2.4
Substance use & addiction journal Pub Date : 2026-10-01 Epub Date: 2026-06-09 DOI:10.1177/29767342261452648
Amelia Bailey, Augustine W Kang, Rosemarie A Martin
{"title":"Advancing Opioid Use Disorder Treatment: A Narrative Review of Evidence-Based Solutions to Systems-Level Barriers in the US.","authors":"Amelia Bailey, Augustine W Kang, Rosemarie A Martin","doi":"10.1177/29767342261452648","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Evidence-based practices to treat opioid use disorder (OUD) include behavioral interventions and medications to treat OUD (MOUD). Each type of treatment has unique systems-level challenges that limit care access and care engagement. It is important to identify and address these challenges and provide evidence-based strategies to reduce barriers.</p><p><strong>Methods: </strong>In this narrative review, systems-level barriers that impede OUD treatment service delivery are reviewed by treatment type (MOUD, cognitive behavioral therapy, and contingency management), and how recent regulatory changes have the ability to reduce or alter these barriers are discussed. To do so, we review empirical literature and regulatory documents to cover the breadth of this topic.</p><p><strong>Results: </strong>Several OUD treatments that have established effectiveness are not able to reach full potential (ie, dissemination, uptake) because of systems-level barriers, notably related to rigid regulations, broad perceptions of treatment, and training and financing constraints. Recent changes aim to lessen restrictions surrounding MOUD delivery (eg, greater allowance for take-home doses of methadone) and allow for delivery of MOUD in innovative settings (eg, mobile health units). There are also reduced restrictions at the treatment provider level, including removal of the X-waiver. Despite lowering some barriers, OUD treatment delivery is still barred by strong forces related dominantly to stigma and financing.</p><p><strong>Conclusions: </strong>Future research directions to further understand and enhance effective OUD treatment delivery are identified, including the need to address individual, organizational, and external factors that surround the implementation of regulatory changes.</p>","PeriodicalId":516535,"journal":{"name":"Substance use & addiction journal","volume":" ","pages":"1244-1256"},"PeriodicalIF":2.4000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Substance use & addiction journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/29767342261452648","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Evidence-based practices to treat opioid use disorder (OUD) include behavioral interventions and medications to treat OUD (MOUD). Each type of treatment has unique systems-level challenges that limit care access and care engagement. It is important to identify and address these challenges and provide evidence-based strategies to reduce barriers.

Methods: In this narrative review, systems-level barriers that impede OUD treatment service delivery are reviewed by treatment type (MOUD, cognitive behavioral therapy, and contingency management), and how recent regulatory changes have the ability to reduce or alter these barriers are discussed. To do so, we review empirical literature and regulatory documents to cover the breadth of this topic.

Results: Several OUD treatments that have established effectiveness are not able to reach full potential (ie, dissemination, uptake) because of systems-level barriers, notably related to rigid regulations, broad perceptions of treatment, and training and financing constraints. Recent changes aim to lessen restrictions surrounding MOUD delivery (eg, greater allowance for take-home doses of methadone) and allow for delivery of MOUD in innovative settings (eg, mobile health units). There are also reduced restrictions at the treatment provider level, including removal of the X-waiver. Despite lowering some barriers, OUD treatment delivery is still barred by strong forces related dominantly to stigma and financing.

Conclusions: Future research directions to further understand and enhance effective OUD treatment delivery are identified, including the need to address individual, organizational, and external factors that surround the implementation of regulatory changes.

推进阿片类药物使用障碍治疗:对美国系统级障碍的循证解决方案的叙述回顾。
背景:治疗阿片类药物使用障碍(OUD)的循证实践包括行为干预和药物治疗。每种类型的治疗都有独特的系统级挑战,限制了护理的可及性和护理参与。重要的是要确定和应对这些挑战,并提供基于证据的战略来减少障碍。方法:在这篇叙述性综述中,根据治疗类型(mod、认知行为治疗和应急管理)回顾了阻碍OUD治疗服务提供的系统级障碍,并讨论了最近的监管变化如何能够减少或改变这些障碍。为此,我们回顾了实证文献和监管文件,以涵盖这一主题的广度。结果:由于系统层面的障碍,特别是与严格的法规、对治疗的广泛认识以及培训和资金限制有关的障碍,一些已经确立有效性的OUD治疗无法充分发挥潜力(即传播和吸收)。最近的变化旨在减少对口服吗啡酮提供的限制(例如,更多地允许美沙酮带回家服用),并允许在创新环境中提供口服吗啡酮(例如,流动卫生单位)。在治疗提供者层面也减少了限制,包括取消x -豁免。尽管降低了一些障碍,但OUD治疗的提供仍然受到主要与污名和融资相关的强大力量的阻碍。结论:未来的研究方向是进一步了解和加强有效的OUD治疗交付,包括需要解决围绕监管变化实施的个人,组织和外部因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书